Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNZ-1 in LGL Leukemia or Refractory CTCL
NCT03239392Phase 2Completed
- Sponsor
- Bioniz Therapeutics, Inc.
- Start
- Apr 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules, PEGylated Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of BNZ-1 in large granular lymphocyte leukemia, cutaneous T-cell lymphoma (CTCL), sponsored by Bioniz Therapeutics, Inc.. Started Apr 2018; status: completed.
02
Drugs
BNZ-1
03
Conditions
large granular lymphocyte leukemiacutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT03239392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239392.